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Summary
 
Despite permitting uncontrolled intracellular visceral infection for 8 wk, interferon-
 
g
 
 (IFN-
 
g
 
)
gene knockout (GKO) mice infected with 
 
Leishmania donovani
 
 proceeded to reduce liver para-
site burdens by 50% by week 12. This late-developing IFN-
 
g
 
–independent antileishmanial
mechanism appeared to be dependent largely on endogenous tumor necrosis factor-
 
a
 
 (TNF-
 
a
 
):
 
L. donovani
 
 infection induced TNF-
 
a
 
 mRNA expression in parasitized GKO livers and neu-
tralization of TNF-
 
a
 
 reversed control at week 12. 7 d of treatment of infected GKO mice with
interleukin-12 (IL-12) readily induced leishmanicidal activity and also partially restored the
near-absent tissue granulomatous response, observations that for the first time expand the anti-
microbial repertoire of IL-12 to include IFN-
 
g
 
–independent effects. The action of IL-12
against 
 
L. donovani
 
 was TNF-
 
a
 
 dependent and required the activity of inducible nitric oxide
synthase. These results point to the presence of an IFN-
 
g
 
–independent antimicrobial mecha-
nism, mediated by TNF-
 
a
 
, which remains quiescent until activated late in the course of exper-
imental visceral leishmaniasis. However, as judged by the effect of exogenous IL-12 this quies-
cent mechanism can readily be induced to rapidly yield enhanced intracellular antimicrobial
activity.
 
I
 
n endogenous and exogenous form, IFN-
 
g
 
 plays a criti-
cal role in the control of experimental visceral leishman-
iasis, an intracellular infection caused by the protozoan,
 
Leishmania donovani
 
 (1, 2). A role for IFN-
 
g
 
–independent
antileishmanial mechanisms in the control or resolution of
visceral leishmaniasis has been suggested (1) but not yet sys-
tematically analyzed in an in vivo environment guaranteed to
be IFN-
 
g
 
 free. IFN-
 
g
 
 gene knockout (GKO)
 
1
 
 mice (3) pro-
vide such an IFN-
 
g
 
–free system and have been used in a
variety of experimental models (3–8). The results reported
here in 
 
L. donovani
 
–infected GKO mice point clearly to
the presence of a novel IFN-
 
g
 
–independent antileishman-
ial mechanism. This mechanism is mediated by endoge-
nous TNF-
 
a
 
 and can be induced by exogenous IL-12.
 
Materials and Methods
 
Animals.
 
GKO mice with a disruption of the gene encoding
IFN-
 
g
 
, bred on a BALB/c background, were provided by Dr. T.
Stewart of Genentech, Inc. (South San Francisco, CA) (3). Ho-
mozygous IFN-
 
g
 
–disrupted (GKO
 
2
 
/
 
2
 
), wild-type (GKO
 
1
 
/
 
1
 
),
or heterozygous (GKO
 
1
 
/
 
2
 
) male and female littermates aged
between 2–7 mo were used. Mice were genotyped by genomic
PCR analysis of tail DNA using standard conditions. Two sets of
primers were added to each reaction: one set spanned a 220-bp
sequence of the nondisrupted endogenous gene; the other set was
specific for a 375-bp sequence in the neomycin-resistance gene
that was part of the foreign DNA disrupting the IFN-
 
g
 
 gene. Su-
pernatants of GKO spleen cell cultures (5 
 
3
 
 10
 
6
 
 cells/ml) either un-
stimulated or stimulated for 24 h with 5 
 
m
 
g/ml Con A (Sigma
Chemical Co., St. Louis, MO) contained 
 
,
 
50 pg/ml of IFN-
 
g
 
 by
ELISA analysis (Endogen, Cambridge, MA). In contrast, culture
supernatants from spleen cells of normal 20–30-g female BALB/c
mice (Charles River Laboratories, Wilmington, MA) contained
 
.
 
3,000 pg/ml of IFN-
 
g
 
 after 24 h of Con A stimulation (data
not shown). Southern blot analysis (9) on BamHI-digested ge-
nomic DNA from mice used for breeding indicated that the IFN-
 
g
 
gene was disrupted as originally described (data not shown) (3).
 
Visceral Infection.
 
Mice were infected intravenously via the tail
vein with 1.5 
 
3
 
 10
 
7
 
 
 
L. donovani
 
 amastigotes (one Sudan strain)
harvested from infected hamster spleen homogenates (10, 11).
The course of infection was assessed by microscopic examination
of Giemsa-stained liver imprints. Liver parasite burdens were quan-
titated as Leishman-Donovan units (LDU) using the number of
liver amastigotes per 500 nuclei 
 
3
 
 liver weight in grams (11).
Liver tissue was also fixed in 10% formalin, and paraffin sections
were stained with hematoxylin and eosin. These slides were scored
for granuloma formation by counting the number of infected foci
in 25 consecutive microscopic fields. Each focus was scored as (
 
a
 
)
no cellular reaction, (
 
b
 
) a core of fused Kupffer cells with no cel-
 
1
 
Abbreviations used in this paper:
 
 AG, aminoguanidine; GKO, gene knock-
out mice; iNOS, inducible nitric oxide synthase; LDU, Leishman-Dono-
van units; NO, nitric oxide; RT, reverse transcriptase.
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lular infiltrate, (
 
c
 
) a developing granuloma with Kupffer cell fu-
sion and some cellular infiltrate, or (
 
d
 
) as a mature granuloma with
the fused core surrounded by a well-developed mononuclear cell
mantle (11).
 
RNA Extraction and Qualitative Reverse Transcriptase–PCR. 
 
Ap-
proximately 50-mg pieces of liver were homogenized in guani-
dine isothiocyanate-phenol solution (RNAzol B; Tel-Test, Inc.,
Friendswood, TX) according to manufacturer’s instructions.
cDNA was synthesized from 
 
z
 
2 
 
m
 
g of total RNA by standard
methods using oligo(dT)
 
18
 
 and MuMLV reverse transcriptase
(RT) (9). cDNA was amplified in a 50-
 
m
 
l reaction volume con-
taining the following: each primer at 2 
 
m
 
M, 200 
 
m
 
M dNTP, 5 
 
m
 
l
10
 
3
 
 buffer with magnesium supplied by the enzyme manufac-
turer (Boehringer Mannheim, Indianapolis, IN), and 1 U of 
 
Taq
 
polymerase. For qualitative PCR, the number of cycles (e.g., 34–
40) was varied to optimize yield of product. As a control for equal
input cDNA, each sample was amplified for GADPH (12).
 
Primers.
 
IFN-
 
g
 
: sense, G AGG GAA TTC CTA GCT CTG
AGA CAA TGA ACG CTA; antisense, TCA AGG ATC CGA
ATC AGC AGC GAC TCC T (13). GADPH: sense, GAT
GAC ATC AAG GTG GT; antisense, TCT TGC TCA GTG
TCC TTG CTG (13). TNF-
 
a
 
: commercially available primers
from Stratagene (La Jolla, CA). iNOS: sense, TCA CGC TTG
GGT CTT GTT CAC T; antisense, TTG TCT CTG GGT
CCT CTG GTC A (14).
 
Treatment with IL-12.
 
Groups of 3–6 mice were continuously
treated for 1 wk with 1 
 
m
 
g/day of murine rIL-12 (7.8 
 
3
 
 10
 
6
 
 U/mg;
Genetics Institute, Cambridge, MA) suspended in saline contain-
ing 1 mg/ml of BSA (10). Subcutaneous osmotic pumps provided
7 d of continuous treatment with IL-12 or saline/BSA (Alzet
model 2001; Alza Corp., Palo Alto, CA). Pumps were implanted
14 d after infection.
 
Treatment of Mice with anti–TNF-
 
a
 
 Antiserum.
 
0.2 ml of rabbit
anti-murine TNF-
 
a
 
 antiserum or normal rabbit serum was injected
intraperitoneally starting on the indicated day after infection and
twice-weekly thereafter (15). The anti–TNF-
 
a
 
 antiserum con-
tained 3 mg/ml IgG with neutralizing activity of 5 
 
3
 
 10
 
4
 
 U/mg
of protein (15).
 
Inhibition of Inducible Nitric Oxide Synthase.
 
Aminoguanidine (AG)
(Sigma), used as an inducible nitric oxide synthase (iNOS) inhib-
itor (16), was given to mice as a 1% solution in drinking water
(wt/vol) starting 12 h after infection and continued for 4 wk.
Water was replaced weekly. At 2 and 4 wk, liver parasite burdens
were determined in AG-treated and untreated controls.
 
Analysis of Data.
 
Data were subjected to a two-tailed Stu-
dent’s 
 
t
 
 test. 
 
P
 
 values of 
 
,
 
0.05 were considered significant.
 
Results
 
Course of L. donovani Infection in GKO Mice.
 
Whereas vis-
ceral infection was controlled by week 4 in IFN-
 
g
 
 gene-
intact littermates (GKO
 
1
 
/
 
1
 
 or GKO
 
1
 
/
 
2
 
) and in normal
BALB/c mice, liver parasite burdens increased dramatically
in GKO mice during the first 8 wk (Fig. 1). These results
confirmed the critical role of endogenous IFN-
 
g
 
 in initial
control of 
 
L. donovani
 
 (1). However, after week 8, parasite
burdens in GKO mice decreased significantly, falling to
50% of peak levels by week 12 (
 
P
 
 
 
,
 
0.05). The results at
week 12 indicated that resolution of visceral leishmaniasis is
initiated by a late-acting IFN-
 
g
 
–independent mechanism.
In one experiment, there were sufficient GKO mice to ex-
tend limited observations to week 16. In this experiment,
mean (
 
6
 
 SEM) liver parasite burdens peaked at week 8
(8932 
 
6
 
 557, 
 
n
 
 
 
5
 
 3) and declined to 5198 
 
6
 
 1457 (
 
n
 
 
 
5
 
3) and 4582 
 
6
 
 60 (mean 
 
6
 
 range, 
 
n
 
 
 
5
 
 2) at weeks 12 and
16, respectively.
 
Granulomatous Tissue Response.
 
Effective control over
visceral replication and eventual resistance to L. donovani is
expressed in the tissues by the assembly of influxing T cells
and monocytes into granulomas at the sites of infection
(11). In this model, hepatic granulomas consist of a core of
fused parasitized Kupffer cells surrounded by a mononu-
clear cell mantle comprised of influxing CD41 and CD81
cells and monocytes (11, 17). As shown in Table 1, control
BALB/c mice displayed the kinetics of granuloma forma-
tion already reported in previous studies (11, 17, 18); how-
ever, the GKO tissue response in the liver differed consid-
erably.
2 wk after infection, 70% of all infected foci in BALB/c
controls had provoked some tissue response, including ma-
ture granuloma formation (Table 1). GKO mice, on the
other hand, showed a scant response to L. donovani at week
2 with 80% of parasitized foci consisted of unfused infected
Kupffer cells with no surrounding mononuclear cells. By
week 4, 56% of BALB/c foci were scored as mature granu-
lomas, structures rarely seen (6%) at this timepoint in GKO
mice (Fig. 2). However, by week 8, there was evidence of
some response at GKO foci, and by week 12, about one in
five GKO foci consisted of fully developed granulomas.
Overall, these results clearly indicate that endogenous IFN-g
regulates optimal recruitment of influxing T cells and mono-
cytes and therefore is required for the initiation of the gran-
ulomatous response early in infection. Nevertheless, there
Figure 1. Course of visceral infection in GKO mice. Results represent
mean LDU 6 SEM from 6–12 animals per timepoint for GKO2/2 (X),
GKO1/1 (j), and BALB/c mice (r); except at week 12 for BALB/c
mice (n 5 4) and GKO1/2 mice (m, identical to GKO1/1 or BALB/c
LDU at all timepoints) (n 5 3).1233 Taylor and Murray
is also some mature granuloma formation in the absence of
IFN-g, reflecting the effect of a late-acting IFN-g–indepen-
dent response.
Role of Endogenous TNF-a in GKO Mice. Because TNF-a
is essential to the resolution of L. donovani infection in nor-
mal BALB/c mice (15), we next focused on TNF-a as a
mechanism that might permit GKO mice to reduce liver
parasite burdens after week 8.
TNF-a mRNA expression in liver was examined using
a qualitative RT-PCR assay in which results can be read
only as positive (visualized on agarose gel) or negative (not
visualized). Although a negative result in this assay does not
imply the absence of cytokine mRNA, conversion within
groups of mice from negative to largely positive qualitative
results, either as infection progressed or after treatment was
given, suggests enhanced mRNA expression. As shown in
Table 2 and Fig. 3, TNF-a mRNA was not detected in GKO
livers using this assay at week 2 but was detected in an in-
creasingly greater proportion of mice as visceral infection
peaked (week 8) and began to resolve (week 12). In livers
of infected normal BALB/c mice (Table 2), this assay
yielded qualitative results that suggested differences in the
kinetics of TNF-a mRNA expression in that expression
was detected earlier and waned by weeks 8–12. These latter
Table 1. Liver Histologic Response to L. donovani Infection
Hepatic infection
and cellular response
Weeks after infection
Normal BALB/c GKO
2 4 8 1 2 248 1 2
Liver burden (LDU) 1,547 537 143 212 3,264 7,648 9,113 4,821
Infected foci 128 147 52 70 123 248 265 172
No cellular reaction (%) 29100 8 0 4 6 2 4 2 2
KC fusion alone (%) 27 11 2 0 12 35 52 39
KD fusion plus infiltrate (%) 27 33 14 2 5 12 17 21
Granulomas (%) 16 56 85 98366 1 8
Liver histologic sections of normal BALB/c and GKO mice were examined for amastigote burdens (LDU) and tissue cellular reactions. 25 3 40
fields were counted and scored as no cellular reaction including no Kupffer cell fusion (KC); fused KC alone; fusion with a developing cellular infil-
trate (early granuloma formation); or fully formed granuloma (11). Results indicate mean values for four mice at each timepoint (eccept BALB/c,
week 12; n 5 3 mice). SEM was ,14%.
Figure 2. Liver histologic re-
action in L. donovani–infected
GKO mice and response to IL-12
treatment. (A) Normal BALB/c
mouse shows mature granuloma
formation surrounding fused par-
asitized Kupffer cell core 4 wk
after infection. (B) 4-wk–infected
GKO liver showing three large
heavily parasitized foci (arrows)
with minimal mononuclear cell
infiltrate. (C) 3-wk–infected un-
treated GKO mouse showing
heavily infected Kupffer cell fo-
cus with no cellular infiltrate. (D)
3-wk–infected GKO mouse
treated  with IL-12 during the
preceding 7 d shows few para-
sites (arrow) and clearly enhanced
cell influx. Original magnifica-
tion,  3630.1234 IL-12 Enhances IFN-g–independent Antileishmanial Activity
results appeared to mirror the more rapid onset of acquired
resistance and control over infection in normal, IFN-g–intact
mice (see Fig. 1).
To analyze the role of TNF-a in the IFN-g–indepen-
dent antileishmanial mechanism, infected GKO animals were
treated with anti–TNF-a antiserum starting at week 8. In
untreated GKO controls, parasite burdens peaked at week 8
and then declined (Table 3). Injections of anti–TNF-a re-
versed this control, whereas injections of normal rabbit se-
rum had no effect. These results indicated that endogenous
TNF-a is required for the control of infection after week 8
in GKO mice, suggesting that TNF-a secretion likely rep-
resented a key IFN-g–independent antileishmanial mecha-
nism.
Response of GKO Mice to Exogenous IL-12. To determine
whether we could activate this initially quiescent IFN-g–inde-
pendent mechanism in infected mice, we examined the ef-
fect of exogenous IL-12. Whereas IL-12 is a potent inducer of
IFN-g expression (Table 4) (19–23) and stimulates IFN-
g–dependent antileishmanial activity in normal BALB/c
mice (10), some reports indicate possible IFN-g–indepen-
dent actions of IL-12 as well (6, 22, 23). GKO mice were
continuously treated with IL-12 starting 2 wk after infec-
tion, and liver burdens were measured 7 d later. During
this period, the parasite burden doubled in untreated mice
(Table 5). In contrast, liver burdens were reduced in IL-12–
treated animals by 34% (week 3 LDU (1687 6 300) versus
week 2 LDU in controls (2556 6 468)) indicating induc-
tion of L. donovani killing. Thus, the IFN-g–independent
mechanism identified here was indeed sensitive to cytokine
upregulation, and despite the absence of IFN-g, IL-12 was
nevertheless quite capable of stimulating an antileishmanial
response.
The IFN-g–independent action of IL-12 was also evi-
dent in the tissue histologic response in GKO mice. In un-
treated 3-wk infected GKO mice, 2% of infected foci were
scored as mature granulomas (two experiments; n 5 4 mice;
see Fig. 2). In contrast, in the same GKO mice treated with
IL-12 for 7 d, 31% of infected foci were scored as mature
granulomas (n 5 4 mice; see Fig. 2). This 15-fold increase
in mature granuloma formation thus correlated with IL-12–
induced IFN-g–independent reduction in liver parasite
burdens.
Table 2. Expression of TNF-a mRNA in
L. donovani–infected Liver
Weeks after
infection Strain
TNF present
no. samples/total (%)
Uninfected GKO 0/4 (0)
BALB/c 0/5 (0)
2 GKO 0/6 (0)
BALB/c 3/6 (50)
4 GKO 3/6 (50)
BALB/c 5/6 (83)
8 GKO 5/6 (83)
BALB/c 3/6 (50)
12 GKO 6/6 (100)
BALB/c 1/6 (17)
Qualitative RT-PCR was performed using cDNA liver samples iso-
lated at the designated timepoints. Results are from 2–3 experiments at
each timepoint.
Figure 3. Kinetics of TNF-a
mRNA expression in BALB/c
mice (A) and GKO mice (B).
Qualitative RT-PCR was per-
formed using cDNA from liver
RNA extracted at each time-
point. Each lane represents one
mouse. Lane 1, size markers; lane
2, PCR control; lanes 3 and 4, 2
wk after infection; lanes 5 and 6,
4 wk after infection; lanes 7 and
8, 8 wk after infection; lanes 9
and 10, 12 wk after infection.
Similar results were obtained
from six mice for each timepoint
from 2–3 separate experiments.1235 Taylor and Murray
Role of TNF-a in IL-12 Action in GKO Mice. Effects of
IL-12 unrelated to IFN-g include upregulation of other
cytokines including TNF-a and GM-CSF (23–25), both of
which induce antileishmanial activity (10, 12). To investi-
gate whether the IFN-g–independent, IL-12–induced anti-
leishmanial response involved TNF-a, 2-wk infected GKO
mice were injected twice-weekly with anti–TNF-a antise-
rum or normal serum during 7 d of IL-12 administration.
As shown in Table 5, there was some nonspecific inhibi-
tion of the effect of IL-12 by simultaneous administration
of control serum; however, injections of anti–TNF-a to-
tally abolished the antileishmanial activity induced by IL-12.
Interaction of IL-12, TNF-a, and iNOS in GKO Mice.
Activated macrophages use at least two mechanisms for
killing intracellular pathogens: the generation of reactive
oxygen intermediates and the induction of l-arginine–depen-
dent toxic reactive nitrogen intermediates (26–34). The lat-
ter includes nitric oxide (NO), the toxic product of iNOS
(30, 35, 36), the induction of which is controlled by cytokines,
e.g., TNF-a in combination with IFN-g (28), and other
stimuli including intracellular pathogens as well (27). There-
fore, we completed this analysis by investigating the mobi-
lization of iNOS as an antileishmanial effector mechanism
in IL-12–treated GKO mice.
iNOS mRNA was not detected in livers of normal unin-
fected BALB/c mice by qualitative RT-PCR, but was de-
tected in these animals at week 3 (3 of 6 mice), and week 4
(5 of 5 mice) after infection (Fig. 4). Although not detected
Table 3. Effect of Anti–TNF-a on Visceral Infection in
GKO Mice
Treatment during
weeks 8–12
Liver Parasite Burden (LDU)
Week 8 Week 12
None (control) 9,788 6 579 4,187 6 636
Normal serum 3,943 6 469
Anti–TNF-a 10,202 6 1,361
Starting 8 wk after infection, GKO mice were injected twice-weekly
with either normal rabbit serum or anti–TNF-a antiserum. Results are
mean LDU 6 SEM from two experiments with 5–6 mice per group.
P ,0.002 for anti–TNF-a–treated group versus untreated and normal
saline-treated mice.
Table 4. IL-12–induced Upregulation of IFN-g in Normal 
BALB/c Mice
Treatment of mice
IFN-g (pg/ml)
Supernatant Serum
Saline/BSA 12 6 9 304 6 271
IL-12 .3,000 .3,000
Mice were given daily intraperitoneal injections of 1 mg of IL-12 for 4 d.
24 h after the last injection, serum was collected and spleen cells were
harvested and cultured in vitro (5 3 106 cells/ml) for an additional 24 h
with no further stimulation. Results are mean 6 SEM values from three
mice per group from a single experiment.
Figure 4. Expression of iNOS mRNA in livers of L. donovani–infected
BALB/c mice. Total liver RNA was isolated at 2, 3, and 4 wk after infec-
tion and assayed for the presence of iNOS message by qualitative RT-
PCR. Each lane represents one mouse. GADPH is a control for the
amount of cDNA in each sample. (A) iNOS RT-PCR: lane 1, size mark-
ers; lane 2, PCR control; lanes 3, 4, and 5, 2-wk samples. GADPH RT-
PCR: lane 1, size markers; lane 2, PCR control; lane 3, blank, lanes 4, 5,
and 6, 2-wk samples. (B) iNOS RT-PCR: lanes 1, 2, and 3: 3-wk sam-
ples; lanes 4, 5, 6, and 7, 4-wk samples from a different gel and PCR re-
action. GADPH RT-PCR, same as iNOS.
Table 5. Effect of IL-12 on Visceral Infection in GKO Mice
Treatment
Liver parasite burdens (LDU)
Week 2 Week 3
None (control) 2,556 6 468 (9) 5,343 6 777 (8)
IL-12 1,687 6 300 (8)*
IL-12 plus anti–TNF-a 8,514 6 782 (8)‡
IL-12 plus control antiserum 2,725 6 288 (9)‡
Saline plus control antiserum 6,428 6 826 (5)
2 wk after infection, GKO mice were treated by pump for 7 d with IL-12
(1 mg/d) or saline. Where indicated, mice were also injected during the
week of IL-12 treatment with either anti–TNF-a antiserum or control
serum given every 3 d starting just after pump insertion. Results are
from three experiments, and represent mean 6 SEM values for (n)
mice.
*Significantly different (P ,0.05) from control mice at week 2 and
week 3.
‡Significantly different (P ,0.05) from control mice at week 3.1236 IL-12 Enhances IFN-g–independent Antileishmanial Activity
in GKO mice at week 3 (0 of 6 mice), iNOS mRNA was
detected at week 4 (4 of 8 mice) (Table 6).
To assess the activity of NO in control of visceral infec-
tion in this model, iNOS was inhibited by oral treatment
with AG (16). In initial experiments, normal BALB/c mice
and wild-type GKO littermates (GKO 1/1) were treated
continuously for 4 wk starting 1 d after infection. As shown
in Table 7, AG treatment inhibited control of visceral in-
fection and allowed a three- to four-fold increase in liver
parasite burdens, indicating an antileishmanial role for iNOS
in normal animals.
Whereas untreated GKO mice did not express detectable
iNOS mRNA 3 wk after infection (0 of 6 mice), iNOS
mRNA was detected in the same mice treated for the pre-
vious 7 d with IL-12 (4 of 6 mice; Table 6). The in vivo
relevance of this effect of IL-12 was tested by simulta-
neously treating GKO mice with IL-12 and AG. As shown
in Table 8, in the presence of AG, the capacity of IL-12 to
induce antileishmanial activity was abrogated. Finally, to
determine whether IL-12–stimulated upregulation of iNOS
involved TNF-a, a recognized participant in iNOS induc-
tion (37), we analyzed liver RNA from GKO mice treated
with both IL-12– and anti–TNF-a. Anti–TNF-a injec-
tions abolished qualitative detection of iNOS mRNA in
IL-12–treated animals (see Table 6).
Discussion
We used GKO mice and a well-established model of ex-
perimental visceral leishmaniasis to characterize host de-
fense responses to intracellular infection in the absence of
IFN-g. Not surprisingly (1), without endogenous IFN-g,
high parasite burdens developed and persisted weeks be-
yond the time infection was controlled in IFN-g–intact
animals. However, despite the key role of macrophage-
activating endogenous IFN-g in the early phases of this in-
fection (1, 2), untreated GKO mice nonetheless prevented
unrestrained infection and reduced liver parasite burdens
after week 8. Thus, because GKO mice produce no IFN-g,
the presence of a late onset IFN-g–independent antileish-
manial mechanism appears unequivocal. GKO mice have
also been used in other experimental models to demon-
strate IFN-g–independent control over infection (4, 8, 45).
While the nature of the antileishmanial mechanism un-
covered here may be multifactorial, our results point to en-
dogenous TNF-a as a primary effector component. In ad-
dition, although persistently quiescent (for unclear reasons)
in the initial stages of visceral infection, this mechanism can
be readily activated early on, as judged by the effects of treat-
ment with exogenous IL-12. This latter result also clearly
expands the host defense repertoire of IL-12 beyond the
induction of IFN-g (10, 22, 24), the most widely studied
antimicrobial action of IL-12. Although our data character-
Table 6. iNOS mRNA Expression in Livers of GKO Mice
Time after infection and treatment
iNOS Detected
No. samples (%)
Uninfected 0/3 (0)
2 Weeks 1/6 (17)
3 Weeks 0/6 (0)
3 Weeks plus IL-12 4/6 (67)
3 Weeks plus IL-12 plus anti-TNF 0/6 (0)
3 Weeks plus IL-12 plus control serum 4/5 (80)
4 Weeks 4/8 (50)
Liver RNA was assayed for the expression of iNOS message by qualita-
tive RT-PCR. Where indicated, IL-12 treatment (1 mg/d for 7 d) was
begun at the end of week 2 with or without simultaneous twice-
weekly injections of anti–TNF-a or normal rabbit serum. Results are
from 2–3 experiments at each timepoint.
Table 7. Effect of Aminoguanidine on L. donovani–infected 
Normal Mice
Strain AG Treatment
Liver parasite burden (LDU)
Week after infection
24
BALB/c 2 1,748 6 125 (6) 569 6 127 (9)
1 1,746 6 74 (6) 2,450 6 255 (9)*
GKO 1/122,854 6 214 (3) 978 6 213 (6)
1 2,166 6 81 (3) 2,919 6 194 (6)*
12 h after L. donovani challenge, treatment with 1% AG was begun and
given continuously for 4 wk. Results are mean 6 SEM values for (n)
mice from two experiments in BALB/c mice and one experiment in
GKO 1/1 mice.
*Significantly different from 4-wk untreated control value (P ,0.05)
Table 8. Effect of iNOS Inhibitor in IL-12–treated GKO Mice
Treatment started
after week 2
Liver parasite burden (LDU)
Weeks after infection
23
None (control) 2,251 6 578 4,665 6 611
IL-12 2 1,539 6 338*
IL-12 plus AG 2 4,545 6 717
Starting 2 wk after infection, GKO mice were treated with IL-12 (1
mg/day) for 7 d with or without the addition of 1% AG to the drinking
water. Results are mean LDU 6 SEM values from two experiments
with 6–10 mice per timepoint.
*Significantly different (P ,0.05) from control mice at week 3.1237 Taylor and Murray
ize the IFN-g–independent effect of exogenous IL-12, we
have not yet determined the possible role of endogenous
IL-12 in the control of L. donovani in GKO mice.
In addition to inducing IFN-g, IL-12 is also known to
enhance expression of TNF-a (23), a cytokine with sepa-
rate effects not necessarily dependent on the presence of
IFN-g as a cofactor (28, 38). In addition, whereas IFN-g
normally induces TNF-a expression by the activated mac-
rophage, some reports indicate IFN-g–independent induc-
tion of TNF-a expression and have suggested that in the
absence of TNF-a, IFN-g is ineffective in control of infec-
tion (30, 31, 37, 39). This latter conclusion is supported by
results from a prior study in IFN-g–intact normal BALB/c
mice (10) in which the antileishmanial effect of exogenous
IL-12 was reversed equally well by either anti–IFN-g or
anti–TNF-a treatment. Whereas these latter results raise
the possibility of a direct effect for TNF-a independent of
IFN-g in normal mice, they appear more consistent with
the notion that both endogenous TNF-a and IFN-g are
required for optimal expression of IL-12–induced antileish-
manial activity (10). However, our results here in GKO mice
clearly suggest that TNF-a induced by exogenous IL-12
(or by L. donovani infection alone) can act by itself in the
absence of IFN-g. In addition, other cytokines with docu-
mented antileishmanial activity such as GM-CSF (12) may
also play a role in the IL-12–stimulated control observed
here; for instance, IL-12 also induces GM-CSF mRNA ex-
pression in livers of infected GKO mice (data not shown).
However, the clear-cut effect of anti–TNF-a in IL-12–
treated GKO mice indicates that TNF-a is both necessary
and sufficient to mediate the effect of IL-12 in the absence
of IFN-g.
It should also be pointed out that treatment of GKO
mice with IL-12 has been reported to induce no protective
effect in models of infection caused by M. tuberculosis and T.
gondii (40, 41). The use of different test pathogens, and varia-
tions in doses of IL-12, or in administration routes and sched-
ules may explain these contrary results. However, another
possible explanation, at least in mycobacterial models, may
relate to the apparently more strict requirement for en-
dogenous IFN-g in defense against these particular patho-
gens (42, 43).
TNF-a and IFN-g act synergistically to induce synthesis
of NO in normal mice (36), and depletion of either cyto-
kine increases mortality after sublethal challenge with vari-
ous microorganisms (31, 44). In GKO mice, NO synthesis
in response to Bacillus Calmette-Guérin infection is depressed
but not absent (3, 35). Similarly, in our model, while qual-
itative detection of iNOS transcription in livers of infected
GKO mice was delayed and apparently incomplete, iNOS
mRNA was detected in 50% of these animals at week 4. In
addition, IL-12 treatment enhanced iNOS mRNA in GKO
mice, also supporting the notion that this antimicrobial
mechanism can be mobilized in the absence of endogenous
IFN-g, likely via endogenous TNF-a (Table 8). The ca-
pacity of the iNOS inhibitor, AG (16), to abolish the anti-
leishmanial effect of IL-12 in GKO mice suggests in vivo
relevance for these observations.
Two particular aspects of granuloma formation in GKO
mice, which was delayed and persistently immature but not
altogether absent, warrant comment. First, single parasitized
Kupffer cells with no evidence of fusion or any surrounding
cellular reaction were present at all timepoints even up to
12 wk after infection. These results (Table 1) provide firm
evidence of the critical role of endogenous IFN-g in mac-
rophage fusion, cell recruitment, and granuloma assembly.
Second, however, the capacity of exogenous IL-12 to accel-
erate and enhance the development of mature granulomas,
an effect not apparent in a previous study in IFN-g–intact
mice (10), also demonstrated a separate IFN-g–independent
pathway active in the tissue granulomatous response. Be-
cause endogenous TNF-a is not essential for granuloma
formation in this model (15), we suspect that factors other
than TNF-a are involved in the tissue reaction stimulated
by IL-12. The activity of GM-CSF, the expression of
which is induced by IL-12 in L. donovani–infected GKO
mice, might be a possible compensatory mechanism of
granuloma assembly in the absence of endogenous IFN-g.
GM-CSF readily stimulates myelomonocytic cell influx into
areas of developing granulomas in L. donovani–parasitized tis-
sues of normal mice (12).
In summary, our results demonstrate the presence of
spontaneously developing and IL-12–inducible intracellular
antileishmanial effects in the absence of endogenous IFN-g,
indicate that this IFN-g–independent mechanism is largely
mediated by TNF-a, and suggest that the iNOS system ap-
pears to be a major antimicrobial effector mechanism in this
IFN-g–independent pathway.
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